1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
BeBetter Med, Inc. Class A

BeBetter Med, Inc. Class A

SSSE:688759
16.90
CNY
-0.70
(-3.98%)
-0.41EPS
14.39BMarket Cap
2020 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
Basic EPS, GAAP
- -
-0.4
-0.41
Free Cash Flow per Basic Share
- -
-0.29
- -
Dividend per Share
- -
- -
- -
Book Value per Share
1.43
3.71
3.54
Tangible Book Value per Share
1.43
3.62
3.45
Basic Weighted Avg Shares
450
385
447
Sales/Revenue/Turnover
- -
- -
- -
Operating Margin (%)
- -
- -
- -
Depreciation Expense
- -
12
- -
Net Income, GAAP
- -
-154
-182
Effective Tax Rate (%)
- -
- -
- -
Profit Margin (%)
- -
- -
- -
Working Capital
125
1,592
1,482
LT Debt
- -
1
1
Total Equity
129
1,669
1,593
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
- -
- -
Return on Common Equity (%)
- -
-17.14
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
ST Debt
3
3
LT Borrowings
- -
- -
LT Finance Leases
1
1
Preferred Equity and Hybrid Capital
- -
- -
Shares Outstanding
450
450
Market Capitalization
16,494
14,392

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Total Current Assets
1,576
1,540
Cash, Cash Equivalents & STI
1,521
1,482
Accounts Receivable, Net
- -
- -
Inventories
- -
- -
Total Current Liabilities
49
57
Payables & Accruals
- -
- -
ST Debt
3
3
Deferred Revenue
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
1,196.45%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.1
-0.08
- -
-0.1
-0.4
2026
-0.12
-0.1
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chang Geng Qian
Full Time Employees
160
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Guangzhou China
IPO Date
Oct 28, 2025
Website
bebettermed.cn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
BeBetter Med, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small-molecule targeted therapeutics for the treatment of cancer, autoimmune diseases, and metabolic disorders. The company develops a specialized pipeline of multi-kinase and epigenetic targeted drugs, including BEBT-908 (Bebetatinib), a dual PI3K and HDAC inhibitor for peripheral T-cell lymphoma, diffuse large B-cell lymphoma, and advanced solid tumors; BEBT-109, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer; BEBT-209, a CDK4/6 inhibitor for hormone receptor-positive, HER2-negative advanced breast cancer; BEBT-260, a pan-RAF inhibitor for BRAF- and RAS-mutant solid tumors; and BEBT-503, a targeted agent for oncology and metabolic indications. Founded in 2012 and headquartered in Guangzhou, China, the company conducts research, laboratory development, and clinical trials primarily in the Asia-Pacific region. In recent developments, BeBetter Med, Inc. advanced the regulatory and registrational development of its lead oncology drug candidate BEBT-908 toward new drug application submission, expanded clinical-stage evaluation of BEBT-209 in combination therapies, accelerated pipeline progress following its listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange, and entered into strategic clinical research partnerships with academic medical institutions to expand its translational oncology portfolio.